<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>45</patient-age><report-id>CA-US-EMD Serono, Inc.-7188390</report-id><gender>female</gender><reactions><reaction>ANGIOGRAM RETINA ABNORMAL</reaction><reaction>RETINOPATHY</reaction><reaction>VISUAL FIELD DEFECT</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REBIF</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Amitriptyline</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Hydromorphone</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Premarin</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10070592</indication></indications><patient-age>45</patient-age><outcomes><outcome>Persistent Or Significant Disability</outcome></outcomes><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000509989</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125161002</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188390</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-16</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-16</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188390</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification code="1">Physician</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>45</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex code="2">Female</patientsex>
      <reaction>
        <primarysourcereaction lang="en">ANGIOGRAM RETINA ABNORMAL</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10002444</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10002444</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">RETINOPATHY</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10038923</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10038923</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">VISUAL FIELD DEFECT</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10047555</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10047555</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>22</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
        <drugdosageform normalized="injection">Injection</drugdosageform>
        <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug code="5">Unknown</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002444</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002444</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038923</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038923</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10047555</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10047555</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>3</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
        <drugdosageform normalized="injection">Injection</drugdosageform>
        <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
        <actiondrug code="5">Unknown</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002444</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002444</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038923</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038923</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10047555</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness>
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10047555</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>Amitriptyline</medicinalproduct>
        <drugdosageform normalized="tablet">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug code="5">Unknown</actiondrug>
        <activesubstance>
          <activesubstancename>AMITRIPTYLINE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10002444</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10038923</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10047555</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Hydromorphone</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Premarin</medicinalproduct>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>This spontaneous case report from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>in Canada was received via Canadian Health Authority (000311033) at Merck Serono on 16 Jan 2013.A 45-year old female patient experienced <Semaphore x="2742547" class="MedDRA LLT" value="Angiogram abnormal" score="1.00" ID="10060956">angiogram <Semaphore x="1130515" class="Medicine" value="Retin-A" score="0.74" ID="239679">retina </Semaphore>abnormal</Semaphore>, <Semaphore x="2467690" class="Disease or Finding" value="Retinopathy" score="1.00" ID="C62601">retinopathy</Semaphore>, <Semaphore x="3315102" class="MedDRA LLT" value="Visual field defect" score="1.00" ID="10047555">visual field defect </Semaphore>while on <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.93" ID="249401">Rebif</Semaphore>.All the events <Semaphore x="2811880" class="MedDRA LLT" value="Blood lead" score="1.00" ID="10005639">led </Semaphore>to patient's <Semaphore x="2909520" class="MedDRA LLT" value="Disability" score="1.00" ID="10013050">disability</Semaphore>. No medical history was reported.The patient's concomitant medications included <Semaphore x="682304" class="Medicine" value="HYDROmorphone" score="0.49" ID="256985">hydromorphone </Semaphore>and <Semaphore x="1082373" class="Medicine" value="Premarin" score="0.49" ID="241366">Premarin </Semaphore>(conjugated <Semaphore x="545141" class="Medicine" value="Estrogens" score="0.49" ID="267891">estrogens</Semaphore>). No further information was provided.The patient received <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.93" ID="249401">Rebif </Semaphore>(<Semaphore x="735013" class="Medicine" value="Interferon beta-1a" score="0.74" ID="273567"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.49" ID="268564">interferon beta </Semaphore>1a</Semaphore>) at a dose of 22 mcg three times a week subcutaneous solution from an unspecified date for an unknown indication. From an unspecified date, <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.93" ID="249401">Rebif </Semaphore>dosage was changed to 44 mcg once every three weeks subcutaneously for 293 days. Additionally, the patient received the following (non Merck Serono) suspected <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>: <Semaphore x="103090" class="Medicine" value="Amitriptyline" score="0.49" ID="280726">amitriptyline </Semaphore>tablet at an unspecified dose for an unknown indication.On an unspecified date, the patient had <Semaphore x="2742547" class="MedDRA LLT" value="Angiogram abnormal" score="1.00" ID="10060956">angiogram <Semaphore x="1130515" class="Medicine" value="Retin-A" score="0.74" ID="239679">retina </Semaphore>abnormal</Semaphore>, <Semaphore x="2467690" class="Disease or Finding" value="Retinopathy" score="1.00" ID="C62601">retinopathy </Semaphore>and <Semaphore x="3315102" class="MedDRA LLT" value="Visual field defect" score="1.00" ID="10047555">visual field defect</Semaphore>. At the time of reporting, action taken with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.93" ID="249401">Rebif </Semaphore>was not reported.At the time of reporting, all the events were not recovered.The reporting <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>did not provide any causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment</Semaphore>.</narrativeincludeclinical>
        <sendercomment lang="en">Angiogram retina abnormal [Angiogram retina abnormal], retinopathy [Retinopathy] and visual field defect [Visual field defect] in a 45-year-old female patient while being treated with Rebif for an unknown indication. 
Temporal relationship: compatible. Latency: not assessable (events onset dates not provided). Dechallenge: not applicable (action taken with Rebif was not reported). 
Alternative explanation: Retinopathy may explain the occurrence of visual field defect. 
Evaluation by reporter (physician): not reported. 
Evaluation by company:  In the absence of sufficient information to fully assess the case, angiogram retina abnormal, retinopathy and visual field defect have been assessed as causally related to Rebif. 
Angiogram retina abnormal, Retinopathy and Visual field defect are unlisted for Rebif as per reference safety information.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>